Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Change in Cash (2022 - 2025)

Bioregenx (BRGX) has 4 years of Change in Cash data on record, last reported at $491.0 in Q3 2025.

  • For Q3 2025, Change in Cash fell 96.13% year-over-year to $491.0; the TTM value through Sep 2025 reached -$23134.0, down 290.91%, while the annual FY2024 figure was -$66998.0, 86.36% up from the prior year.
  • Change in Cash reached $491.0 in Q3 2025 per BRGX's latest filing, up from -$37169.0 in the prior quarter.
  • Across five years, Change in Cash topped out at $67439.0 in Q4 2023 and bottomed at -$224118.0 in Q2 2023.
  • Average Change in Cash over 4 years is -$39562.1, with a median of -$11244.0 recorded in 2024.
  • The widest YoY moves for Change in Cash: up 7896.42% in 2023, down 28655.33% in 2023.
  • A 4-year view of Change in Cash shows it stood at -$865.0 in 2022, then skyrocketed by 7896.42% to $67439.0 in 2023, then crashed by 117.31% to -$11677.0 in 2024, then skyrocketed by 104.2% to $491.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $491.0 in Q3 2025, -$37169.0 in Q2 2025, and $25221.0 in Q1 2025.